Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

A National Multicenter Phase I/IIa Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis.

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of CD19 CAR-T cell therapy (TranspoCART19) in adults with refractory lupus nephritis. Lupus nephritis is a serious kidney complication of systemic lupus erythematosus that may not respond adequately to standard treatments. The main questions this study aims to answer are: * Is TranspoCART19 safe and tolerable in patients with refractory lupus nephritis? * Can TranspoCART19 induce complete or partial clinical and immunological remission? Participants will: * Undergo leukapheresis to collect immune cells for manufacturing TranspoCART19. * Receive lymphodepleting chemotherapy before treatment. * Receive a single fractionated infusion of TranspoCART19. * Attend regular follow-up visits for safety, disease activity, kidney function, immune response, and quality-of-life assessments for up to 24 months, with long-term safety follow-up after study completion.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Ability and willingness to provide written informed consent.

• Adults aged ≥18 and ≤65 years with a diagnosis of systemic lupus erythematosus (SLE) according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria.

• Positive antinuclear antibody (ANA) result at a titer \>1:80, or positive anti-double stranded DNA (anti-dsDNA), or positive anti-Smith (anti-Sm) antibodies at screening.

• Diagnosis of class III or IV proliferative lupus nephritis, with or without concomitant class V disease, confirmed by renal biopsy demonstrating active lupus nephritis according to the 2018 ISN/RPS classification.

• Evidence of refractory or treatment-resistant lupus nephritis according to GLOSEN criteria.

• Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² during the screening period.

• Urine protein-to-creatinine ratio (UPCR) \>0.7 g/g, urine albumin-to-creatinine ratio (UACR) \>0.5 g/g, proteinuria \>0.7 g/24 h, or albuminuria \>0.5 g/24 h at screening with evidence of active lupus nephritis.

• Stable treatment with an ACE inhibitor, angiotensin receptor blocker and/or mineralocorticoid receptor antagonist (with or without an SGLT2 inhibitor) for at least 3 months prior to screening, unless contraindicated or not tolerated.

• Adequate venous access and no contraindication to leukapheresis.

⁃ Women of childbearing potential must have a negative pregnancy test at screening, prior to lymphodepletion and prior to infusion, and must agree to use highly effective contraception. Sexually active men must agree to use condoms and comply with protocol-specified reproductive precautions.

⁃ Completion of recommended vaccinations, including SARS-CoV-2 vaccination/immunization, before study treatment.

⁃ Ability and willingness to comply with all study procedures and follow-up requirements.

Locations
Other Locations
Spain
Hospital Germans Trias i Pujol
NOT_YET_RECRUITING
Badalona
Hospital Universitario de León
NOT_YET_RECRUITING
León
Hospital Universitario Fundación Jiménez Diaz
NOT_YET_RECRUITING
Madrid
Hospital Clínico Universitario Virgen de la Arrixaca
NOT_YET_RECRUITING
Murcia
Clinica Universidad de Navarra
RECRUITING
Pamplona
Hospital Universitario de Salamanca
NOT_YET_RECRUITING
Salamanca
Hospital Clínico Universitario de Santiago
NOT_YET_RECRUITING
Santiago De Compostela
Hospital Universitario Virgen del Rocio
NOT_YET_RECRUITING
Seville
Contact Information
Primary
Lucia Llanos
lucia.llanos@quironsalud.es
91 5504800
Backup
Eva Cerezo
eva.cerezo@quironsalud.es
91 5504800
Time Frame
Start Date: 2026-09-23
Estimated Completion Date: 2030-09
Participants
Target number of participants: 10
Treatments
Experimental: TranspoCART19
Participants with refractory lupus nephritis will undergo leukapheresis for manufacturing of autologous TranspoCART19 cells, followed by lymphodepleting chemotherapy and administration of TranspoCART19 as a fractionated intravenous infusion at a target dose of 1 × 10\^6 CAR-T cells per kg.
Sponsors
Leads: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

This content was sourced from clinicaltrials.gov

Similar Clinical Trials